Abstract 125P
Background
BTC is a diverse group of hepatic and perihepatic malignancies with a 5-year survival rate of <20%. This study described real-world treatment patterns and outcomes among patients with advanced and/or unresectable (aBTC) in France, Germany, Italy, Spain, and the United Kingdom (UK).
Methods
In this retrospective, web-based chart review survey, physicians reported anonymized patient-level data for adult patients diagnosed with aBTC between May 2018 and October 2021 who received first-line (1L) systemic therapy (index date). Patients were followed from index date until death or last available date at abstraction. Patient characteristics, treatment patterns, and clinical outcomes were summarized descriptively.
Results
A total of 196 physicians extracted data for 792 aBTC patients who initiated 1L systemic therapy. More patients had intrahepatic cholangiocarcinoma (CCA; 34.8%), than extrahepatic CCA (29.9%), gallbladder (23.5%), and ampullary cancer (10.2%) whereas 1.5% patients had missing information. During follow-up (median=12.4 months), less than half of patients were prescribed gemcitabine + cisplatin (GemCis; 47.9%) as 1L. Median 1L treatment duration was 5.3 months with disease progression (49.2%) being the most common reason for treatment discontinuation. Only 33.1% received 2L and 4.1% received 3L+ of treatment. Median real-world overall survival (rwOS) from index date was 13.4 months, with regional variation (Table).
Table: 125P
Key results by country*
France (N = 167) | Germany (N = 150) | Italy (N = 153) | Spain (N = 167) | UK (N = 155) | |
Male, % | 67.1 | 66.7 | 55.6 | 65.9 | 57.4 |
Age ≥60, % | 73.1 | 60.7 | 76.5 | 76.0 | 85.2 |
Site of primary BTC tumor, % | |||||
Intrahepatic CCA | 31.1 | 35.3 | 51.0 | 28.7 | 29.0 |
Extrahepatic CCA | 30.5 | 28.0 | 26.8 | 29.3 | 34.8 |
Gallbladder | 23.4 | 29.3 | 11.1 | 28.7 | 24.5 |
Ampulla of Vater | 13.8 | 6.0 | 9.8 | 13.2 | 7.7 |
Unknown | 1.2 | 1.3 | 1.3 | 0 | 3.9 |
ECOG at diagnosis, % | |||||
0 | 20.4 | 14.7 | 27.5 | 18.6 | 32.9 |
1 | 52.1 | 48.0 | 64.1 | 67.7 | 52.3 |
2+ | 22.2 | 22.0 | 8.5 | 11.4 | 11.6 |
Unknown | 5.4 | 15.3 | 0 | 2.4 | 3.2 |
GemCis 1L regimen, % | 28.7 | 30.0 | 69.9 | 44.3 | 67.7 |
Median rwOS (months) | 17.8 | 18.3 | 14.7 | 13.1 | 8.8 |
*All decimals have been rounded to the nearest tenth, thus the overall % may result in getting a value slightly higher than 100%.
Conclusions
This study demonstrated the unmet needs of patients with aBTC, with less than half of the patients receiving standard-of-care – GemCis (ESMO recommendation) and a median rwOS of just over one year suggesting the need for new treatments that extend survival. With the recent approval of immunotherapy for aBTC patients, exploration of the benefits in real-world is needed. Additional efforts in the earlier detection of BTC are essential to improve survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
J.A. Bridgewater: Financial Interests, Personal, Advisory Board: Taiho, BMS, Incyte, Basilea, Servier; Financial Interests, Institutional, Funding: Incyte. M. Paskow: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. A. Szende: Financial Interests, Personal, Full or part-time Employment: Labcorp Drug Development; Financial Interests, Personal, Stocks/Shares: Labcorp Drug Development. P. Messina: Financial Interests, Personal, Full or part-time Employment: Labcorp, IQVIA. J. Sah: Financial Interests, Personal, Stocks/Shares: AstraZeneca; Financial Interests, Personal, Full or part-time Employment: AstraZeneca. B. Baur: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca.
Resources from the same session
679P - Lurbinectedin (LRB) pharmacokinetics (PK) and safety when co-administered with itraconazole (ITZ) in patients with advanced solid tumor
Presenter: Irene Moreno
Session: Poster session 17
680P - First results from the phase I trial of the ATR inhibitor, ART0380, in advanced solid tumors
Presenter: Kathleen Moore
Session: Poster session 17
681P - First-in-human study of ATR inhibitor IMP9064 monotherapy and in combination with PARP inhibitor senaparib in patients with advanced solid tumors
Presenter: Chia-Chi Lin
Session: Poster session 17
683P - Preclinical evaluation of HLX42, a novel EGFR-targeting ADC, for cetuximab or TKI resistant cancer
Presenter: Yongqiang Shan
Session: Poster session 17
684P - Phase I trial of SHR-A1811 in HER2-expressing advanced gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) and colorectal cancer (CRC)
Presenter: Jin Li
Session: Poster session 17
685P - BL-M07D1, a HER2 antibody-drug conjugate in subjects with locally advanced or metastatic HER2 expressing breast cancer and other solid tumors
Presenter: Erwei Song
Session: Poster session 17
686P - Phase I study of HRS8807, an oral selective ER covalent antagonist (SERCA), in ER+/HER2- locally advanced (LA) or metastatic (M) breast cancer (BC)
Presenter: Jiong Wu
Session: Poster session 17
687P - A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER3 antibody) in patients with advanced HER3 positive solid tumours
Presenter: Johann de Bono
Session: Poster session 17
688P - Pharmacokinetics of HMBD-001, a human monoclonal antibody targeting HER3, a CRUK first-in-human phase I trial in patients with advanced solid tumours
Presenter: Oladipo Idowu
Session: Poster session 17
689P - DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study
Presenter: Omkar Marathe
Session: Poster session 17